Overview Performance Dividends Fundamentals Peer Group Correlations Pair Trades Institutions Insider Forecasts Options

Performance of NOV Novo Nordisk A/S | 55.6% in 12m

Compare NOV with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?

Compare Novo Nordisk A/S with its related Sector/Index XBI

Compare Novo Nordisk A/S with its related Sector/Index XBI

Performance Duell NOV vs XBI

TimeFrame NOV XBI
1 Week 4.04% 3.39%
1 Month -0.82% 3.58%
3 Months -4.22% 10.45%
6 Months 10.9% 7.00%
12 Months 55.6% 33.45%
YTD 44.2% 12.31%
Rel. Perf. 1m -0.03
Rel. Perf. 3m -1.14
Rel. Perf. 6m 0.21
Rel. Perf. 12m 0.21
Spearman 1m -0.22 -0.17
Spearman 3m -0.48 0.62

Is Novo Nordisk A/S a good stock to buy?

Partly, yes. Based on ValueRay Fundamental Analyses, Novo Nordisk A/S (XETRA:NOV) is currently (September 2024) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 47.90 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NOV as of September 2024 is 180.86. This means that NOV is currently undervalued and has a potential upside of +46.28% (Margin of Safety).

Is NOV a buy, sell or hold?

Novo Nordisk A/S has no consensus analysts rating. ValueRay therefore judges the recommendation based on the last 12 Month Returns of 55.55%.

In compare to SPDR S&P Biotech, NOV made 22.1% more over the last 12 months. Due to the outperformance, it is recommend to buy NOV.
Values above 0%: NOV is performing better - Values below 0%: NOV is underperforming

Compare NOV with Broad Market Indices

Symbol 1w 1m 6m 12m
US S&P 500 SPY 1.19% -2.44% 0.27% 27.55%
US NASDAQ 100 QQQ -0.55% -1.01% 1.00% 26.61%
US Dow Jones Industrial 30 DIA 2.60% -3.13% 3.05% 33.88%
German DAX 40 DBXD 2.68% -3.67% 7.12% 35.96%
UK FTSE 100 ISFU 3.37% -2.32% -1.69% 38.04%
Shanghai Shenzhen CSI 300 CSI 300 4.75% 3.32% 19.60% 67.09%
Hongkong Hang Seng HSI 3.79% -3.26% 11.38% 59.80%
Japan Nikkei 225 EXX7 1.90% -2.96% 12.95% 41.98%
India NIFTY 50 INDA 2.46% -4.36% -3.65% 27.48%
Brasil Bovespa EWZ 3.43% 0.71% 15.41% 57.24%

NOV Novo Nordisk A/S vs. Sectors

Symbol 1w 1m 6m 12m
Communication Services XLC 0.78% -1.83% 0.71% 25.63%
Consumer Discretionary XLY 0.03% -6.17% 2.29% 41.38%
Consumer Staples XLP 3.68% -5.35% -1.92% 35.57%
Energy XLE 5.24% 4.68% 15.87% 60.22%
Financial XLF 5.02% -3.26% 0.90% 25.91%
Health Care XLV 3.31% -3.08% 2.62% 35.32%
Industrial XLI 1.89% -3.51% 3.17% 29.33%
Materials XLB 1.91% -3.29% 7.92% 39.32%
Real Estate XLRE 1.64% -8.77% -6.92% 27.11%
Technology XLK -2.32% -0.55% 3.29% 24.65%
Utilities XLU 1.61% -6.80% -14.93% 30.37%
Aerospace & Defense XAR 2.13% -2.45% -0.58% 23.56%
Biotech XBI 0.65% -4.40% 3.86% 22.10%
Homebuilder XHB -2.27% -8.53% -3.12% 3.27%
Retail XRT -0.05% 0.46% 10.28% 30.45%

NOV Novo Nordisk A/S vs. Commodities

Symbol 1w 1m 6m 12m
Oil USO 3.22% 8.96% 19.36% 69.80%
Natural Gas UNG -3.45% -0.27% 15.09% 103.43%
Gold GLD 0.98% -6.01% -8.65% 22.50%
Silver SLV -4.35% -9.17% -10.81% 24.00%
Copper CPER 1.87% -2.51% 8.18% 42.39%

Returns of NOV vs. Yields & Bonds

Symbol 1w 1m 6m 12m
iShares 20+ Years Bond TLT 3.62% -4.56% 0.64% 43.84%
iShares High Yield Corp. Bond HYG 3.66% -2.63% 4.35% 42.22%
Does Novo Nordisk A/S outperform its market, is NOV a Sector Leader?
Yes, over the last 12 months Novo Nordisk A/S (NOV) made 55.55%, while its related Sector, the SPDR S&P Biotech (XBI) made 33.45%.
Over the last 3 months NOV made -4.22%, while XBI made 10.45%.
Period NOV XBI S&P 500
1 Month -0.82% 3.58% 1.62%
3 Months -4.22% 10.45% 3.88%
12 Months 55.55% 33.45% 28.00%